University of California

Pfizer Corporation

Leland Stanford Junior University

Other

Harvard College

The United States Government As Represented by the Department of Veterans Affairs

Jeffrey A Bluestone

Jennifer A Doudna

Natasha K Crellin

Lauren K Ely

Amy Putnam

Qizhi Tang

Eleonora Trotta

Weihong Liu

Kenan Christopher Garcia

Paul Henry Bessette

Isaac J Rondon

Lewis L Lanier

Linda K Jolliffe

Alexander Marson

Robert Allan Zivin

Michael A Fischbach

Jon Clardy

Matthias Hebrok

Gopika G Nair

Wenhan Chang

Jason Robles Reyes

Thuy Vo

Steven Lin

Eleonora De Klerk

Gaetano Faleo

Peter Stock

Casey Ward

Caroline Raffin

Chia Chi Ho

Cristina Penaranda

Laura Brown

Emma Masteller

Koetsu Ogasawara

Kathrin Schumann

The invention provides methods of isolating CD 127immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.

CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs

Chimeric antigen receptor (CAR)-expressing Tregs specifically target an antigen present in the joint of RA patients to induce a localized and effective immunosuppressive response.

CAR-t cells and autoimmune diseases

The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.

Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions

Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.

Preservation of pancreatic islet grafts in the extrahepatic space

The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R&#x3b1; and IL-2R&#x3b2;. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

Anti-IL-2 antibodies and compositions and uses thereof

The invention provides methods of isolating CD127immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.

[object Object]

Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.

Glycosphingolipids for use in modulating immune responses

CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ tregs

The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.

Expansion of alloantigen-reactive regulatory T cells

The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.

Modulation of NKG2D for prolonging survival of a hematopoietic graft

The invention provides methods for producing an autoantigen-specific regulatory T cell enriched composition, and resultant compositions and methods of use.

Regulatory T cells suppress autoimmunity

The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. These &ldquo;humanized&rdquo; anti-CD3 monoclonal antibodies retain, in vitro, all the properties of native anti-CD3 antibodies, including T cell activation which has been correlated, in vivo, with the severe side-effects observed in transplant recipients after the first administration of the mAb.

Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies

Growing community of inventors

San Francisco, CA, United States of America

Jeffrey A Bluestone